BACKGROUND: The economic cost of dementia is high and can be predicted by cognitive and neuropsychiatric profiles. The differential costs of the various subtypes of dementia are unknown in Argentina, and this study therefore aimed to compare these costs. METHODS: Patients with a diagnosis of dementia of Alzheimer-type (DAT), frontotemporal dementia (FTD) and vascular dementia (VaD), and their primary caregivers, were evaluated between 2002 and 2008. RESULTS: 104 patients with dementia (DAT = 44, FTD = 34, VaD = 26) were screened and matched by age and educational level with 29 healthy subjects. Demographic variables showed no significant differences among dementia patients. The annual direct costs were US$4625 for DAT, US$4924 for FTD, and US$5112 for VaD (p > 0.05 between groups). In the post hoc analysis VaD showed higher hospitalization costs than DAT (p < 0.001). VaD exhibited lower medication costs than FTD (p < 0.001). DAT exhibited higher anti-dementia drug costs; FTD had higher psychotropic costs. In the multivariate analysis, depression, activities of daily living, and caregiver burden were correlated with direct costs (r2 = 0.76). CONCLUSIONS: The different dementia types have different costs. Overall, costs increased with the presence of behavioral symptoms, depression and functional impairment of activities of daily living.
BACKGROUND: The economic cost of dementia is high and can be predicted by cognitive and neuropsychiatric profiles. The differential costs of the various subtypes of dementia are unknown in Argentina, and this study therefore aimed to compare these costs. METHODS:Patients with a diagnosis of dementia of Alzheimer-type (DAT), frontotemporal dementia (FTD) and vascular dementia (VaD), and their primary caregivers, were evaluated between 2002 and 2008. RESULTS: 104 patients with dementia (DAT = 44, FTD = 34, VaD = 26) were screened and matched by age and educational level with 29 healthy subjects. Demographic variables showed no significant differences among dementiapatients. The annual direct costs were US$4625 for DAT, US$4924 for FTD, and US$5112 for VaD (p > 0.05 between groups). In the post hoc analysis VaD showed higher hospitalization costs than DAT (p < 0.001). VaD exhibited lower medication costs than FTD (p < 0.001). DAT exhibited higher anti-dementia drug costs; FTD had higher psychotropic costs. In the multivariate analysis, depression, activities of daily living, and caregiver burden were correlated with direct costs (r2 = 0.76). CONCLUSIONS: The different dementia types have different costs. Overall, costs increased with the presence of behavioral symptoms, depression and functional impairment of activities of daily living.
Authors: Yingjia Chen; Leslie Wilson; John Kornak; R Adams Dudley; Jennifer Merrilees; Stephen J Bonasera; Christie M Byrne; Kirby Lee; Winston Chiong; Bruce L Miller; Katherine L Possin Journal: Alzheimers Dement Date: 2019-06-04 Impact factor: 21.566
Authors: Carol Dillon; Cecilia M Serrano; Diego Castro; Patricio Perez Leguizamón; Silvina L Heisecke; Fernando E Taragano Journal: Neuropsychiatr Dis Treat Date: 2013-09-19 Impact factor: 2.570
Authors: Jennifer C Davis; Ging-Yuek Robin Hsiung; Stirling Bryan; John R Best; Janice J Eng; Michelle Munkacsy; Winnie Cheung; Bryan Chiu; Claudia Jacova; Philip Lee; Teresa Liu-Ambrose Journal: BMJ Open Date: 2017-03-29 Impact factor: 2.692
Authors: Agustin Ibáñez; Stefanie Danielle Pina-Escudero; Katherine L Possin; Yakeel T Quiroz; Fernando Aguzzoli Peres; Andrea Slachevsky; Ana Luisa Sosa; Sonia M D Brucki; Bruce L Miller Journal: Lancet Healthy Longev Date: 2021-03-31
Authors: Nilton Custodio; David Lira; Eder Herrera-Perez; Liza Nuñez Del Prado; José Parodi; Erik Guevara-Silva; Sheila Castro-Suarez; Rosa Montesinos Journal: Dement Neuropsychol Date: 2015 Jan-Mar